GSK Acquires Global Rights to Chinese-Developed Multiple Myeloma Treatment

Source Summary

GlaxoSmithKline has acquired global rights to a multiple myeloma treatment developed in China as part of its ongoing effort to expand its drug pipeline. The deal represents GSK's continued strategy of in-licensing therapies to strengthen its portfolio.

Why it matters

The acquisition strengthens GSK's oncology pipeline and demonstrates its strategy to source innovative treatments globally to address unmet medical needs.